“The Phase I studies aim to establish the safety and appropriate dosing of GX-I7, with the goal of preventing severe COVID-19 progression in people most susceptible to infection, such as seniors or those with comorbidities.” AND “Coronavirus found to suppress immune response, but this new therapy can restore immune function”

https://www.genengnews.com/covid-19-candidates/genexine-and-neoimmunetech-nit-gx-i7-also-called-nt-17-or-hyleukin-7-rhil-7-hyfc/

“The Phase I studies aim to establish the safety and appropriate dosing of GX-I7, with the goal of preventing severe COVID-19 progression in people most susceptible to infection, such as seniors or those with comorbidities.”

Candidate: GX-I7, also known as NT-17 or Hyleukin-7™ (rhIL-7-hyFc)

Type: Homeostatic T cell growth factor composed of a covalently linked homodimer of engineered #Interleukin-7 (IL-7) molecule, biologically fused with the proprietary long-acting platform – hyFc™.

#SARSCoV2 #IL7 #GXI7

See also: https://www.naturalnews.com/2020-08-23-coronavirus-suppresses-immune-therapy-restores.html

“Coronavirus found to suppress immune response, but this new therapy can restore immune function”